Trial Outcomes & Findings for Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (NCT NCT01024231)
NCT ID: NCT01024231
Last Updated: 2021-03-22
Results Overview
incidence of all cause and treatment related adverse events
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
127 participants
Primary outcome timeframe
Up to 3 years
Results posted on
2021-03-22
Participant Flow
127 Randomized and Treated
Participant milestones
| Measure |
Cohort 1
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 6
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
3 mg/kg of BMS-936558 (MDX-1106)
|
Cohort 8
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
14
|
17
|
16
|
6
|
17
|
16
|
41
|
|
Overall Study
COMPLETED
|
2
|
2
|
6
|
1
|
0
|
0
|
20
|
|
Overall Study
NOT COMPLETED
|
12
|
15
|
10
|
5
|
17
|
16
|
21
|
Reasons for withdrawal
| Measure |
Cohort 1
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 6
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
3 mg/kg of BMS-936558 (MDX-1106)
|
Cohort 8
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
|---|---|---|---|---|---|---|---|
|
Overall Study
Other Reasons
|
1
|
2
|
0
|
0
|
2
|
0
|
1
|
|
Overall Study
Maximum Clinical Benefit
|
1
|
2
|
0
|
1
|
1
|
0
|
0
|
|
Overall Study
Disease Progression
|
3
|
1
|
3
|
0
|
4
|
11
|
6
|
|
Overall Study
AE unrelated to Study Drug
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
No longer meets criteria
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
|
Overall Study
Study Drug Toxicity
|
1
|
6
|
6
|
4
|
2
|
0
|
7
|
|
Overall Study
Death
|
6
|
2
|
1
|
0
|
4
|
3
|
5
|
|
Overall Study
Lost to Follow-up
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Overall Study
Withdrew Consent
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
Overall Study
Continuing on Treatment
|
0
|
0
|
0
|
0
|
3
|
2
|
0
|
Baseline Characteristics
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Baseline characteristics by cohort
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Total
n=127 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
57.9 Years
STANDARD_DEVIATION 9.58 • n=5 Participants
|
53.5 Years
STANDARD_DEVIATION 14.14 • n=7 Participants
|
59.1 Years
STANDARD_DEVIATION 14.65 • n=5 Participants
|
56.2 Years
STANDARD_DEVIATION 11.99 • n=4 Participants
|
63.9 Years
STANDARD_DEVIATION 14.37 • n=21 Participants
|
60.6 Years
STANDARD_DEVIATION 17.56 • n=8 Participants
|
55.2 Years
STANDARD_DEVIATION 15.83 • n=8 Participants
|
57.6 Years
STANDARD_DEVIATION 13.78 • n=24 Participants
|
|
Age, Customized
<65 Years
|
11 Participants
n=5 Participants
|
14 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
7 Participants
n=21 Participants
|
11 Participants
n=8 Participants
|
32 Participants
n=8 Participants
|
90 Participants
n=24 Participants
|
|
Age, Customized
≥ 65 Years
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
9 Participants
n=8 Participants
|
37 Participants
n=24 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=5 Participants
|
7 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
8 Participants
n=21 Participants
|
7 Participants
n=8 Participants
|
23 Participants
n=8 Participants
|
59 Participants
n=24 Participants
|
|
Sex: Female, Male
Male
|
9 Participants
n=5 Participants
|
10 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
9 Participants
n=21 Participants
|
9 Participants
n=8 Participants
|
18 Participants
n=8 Participants
|
68 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
14 Participants
n=5 Participants
|
17 Participants
n=7 Participants
|
16 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
15 Participants
n=21 Participants
|
16 Participants
n=8 Participants
|
39 Participants
n=8 Participants
|
123 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
|
Race (NIH/OMB)
White
|
14 Participants
n=5 Participants
|
17 Participants
n=7 Participants
|
16 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
16 Participants
n=21 Participants
|
16 Participants
n=8 Participants
|
37 Participants
n=8 Participants
|
122 Participants
n=24 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
PRIMARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants
incidence of all cause and treatment related adverse events
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With an Adverse Event (AE)
Treatment Related
|
13 Participants
|
17 Participants
|
15 Participants
|
6 Participants
|
51 Participants
|
15 Participants
|
13 Participants
|
28 Participants
|
40 Participants
|
91 Participants
|
119 Participants
|
|
Number of Participants With an Adverse Event (AE)
All Cause
|
14 Participants
|
17 Participants
|
16 Participants
|
6 Participants
|
53 Participants
|
17 Participants
|
16 Participants
|
33 Participants
|
41 Participants
|
94 Participants
|
127 Participants
|
PRIMARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants
incidence of all cause and treatment related serious adverse events
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With a Serious Adverse Event (AE)
All Cause
|
10 Participants
|
15 Participants
|
10 Participants
|
5 Participants
|
40 Participants
|
9 Participants
|
10 Participants
|
19 Participants
|
26 Participants
|
66 Participants
|
85 Participants
|
|
Number of Participants With a Serious Adverse Event (AE)
Treatment Related
|
5 Participants
|
13 Participants
|
9 Participants
|
4 Participants
|
31 Participants
|
4 Participants
|
4 Participants
|
8 Participants
|
18 Participants
|
49 Participants
|
57 Participants
|
PRIMARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants
incidence of all cause and treatment related adverse events which lead to discontinuation
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With an Adverse Event (AE) Which Lead to Discontinuation
All Cause
|
2 Participants
|
8 Participants
|
5 Participants
|
1 Participants
|
16 Participants
|
5 Participants
|
1 Participants
|
6 Participants
|
13 Participants
|
29 Participants
|
35 Participants
|
|
Number of Participants With an Adverse Event (AE) Which Lead to Discontinuation
Treatment Related
|
2 Participants
|
6 Participants
|
5 Participants
|
1 Participants
|
14 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
11 Participants
|
25 Participants
|
27 Participants
|
PRIMARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants
incidence of all cause and treatment related deaths
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Deaths
All Cause
|
8 Participants
|
4 Participants
|
2 Participants
|
0 Participants
|
14 Participants
|
7 Participants
|
8 Participants
|
15 Participants
|
8 Participants
|
22 Participants
|
37 Participants
|
|
Number of Deaths
Treatment Related
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants
incidence of all cause and treatment related Adverse events in certain organ systems
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With Select AEs
Renal
|
2 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
5 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
6 Participants
|
7 Participants
|
|
Number of Participants With Select AEs
Endrocrine
|
2 Participants
|
5 Participants
|
3 Participants
|
3 Participants
|
13 Participants
|
4 Participants
|
1 Participants
|
5 Participants
|
12 Participants
|
25 Participants
|
30 Participants
|
|
Number of Participants With Select AEs
Gastrointestinal
|
5 Participants
|
7 Participants
|
10 Participants
|
4 Participants
|
26 Participants
|
3 Participants
|
4 Participants
|
7 Participants
|
20 Participants
|
46 Participants
|
53 Participants
|
|
Number of Participants With Select AEs
Hepatic
|
5 Participants
|
6 Participants
|
4 Participants
|
3 Participants
|
18 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
8 Participants
|
26 Participants
|
28 Participants
|
|
Number of Participants With Select AEs
Pulmonary
|
1 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
6 Participants
|
7 Participants
|
|
Number of Participants With Select AEs
Skin
|
12 Participants
|
15 Participants
|
15 Participants
|
4 Participants
|
46 Participants
|
8 Participants
|
10 Participants
|
18 Participants
|
34 Participants
|
80 Participants
|
98 Participants
|
|
Number of Participants With Select AEs
Hypersensitivity/Infusion Reaction
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
5 Participants
|
PRIMARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants
Number of Participants with On-Treatment Laboratory Abnormalities in Specific Liver Tests Aspartate aminotransferase (AST) Alanine aminotransferase (ALT) Upper Limit of Normal (ULN)
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Laboratory Abnormalities: Specific Liver Tests
ALT or AST > 3xULN
|
1 Participants
|
0 Participants
|
2 Participants
|
3 Participants
|
6 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
6 Participants
|
12 Participants
|
13 Participants
|
|
Laboratory Abnormalities: Specific Liver Tests
ALT or AST > 5xULN
|
3 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
6 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
5 Participants
|
11 Participants
|
11 Participants
|
|
Laboratory Abnormalities: Specific Liver Tests
ALT or AST > 10xULN
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
5 Participants
|
5 Participants
|
|
Laboratory Abnormalities: Specific Liver Tests
ALT or AST > 20xULN
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
4 Participants
|
4 Participants
|
|
Laboratory Abnormalities: Specific Liver Tests
Total Bilirubin (Tbili) > 2xULN
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
|
Laboratory Abnormalities: Specific Liver Tests
ALT or AST > 3xULN w/ Tbili > 2xULN within 1 day
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
PRIMARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants
Number of Participants with On-Treatment Laboratory Abnormalities in Specific Thyroid Tests Free T3 (FT3) Free T4 (FT4) Lower Limit of Normal (LLN)
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH > ULN with TSH≤ ULN @ Baseline
|
3 Participants
|
6 Participants
|
7 Participants
|
1 Participants
|
17 Participants
|
3 Participants
|
1 Participants
|
4 Participants
|
6 Participants
|
23 Participants
|
27 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH > ULN
|
7 Participants
|
9 Participants
|
7 Participants
|
3 Participants
|
26 Participants
|
4 Participants
|
3 Participants
|
7 Participants
|
8 Participants
|
34 Participants
|
41 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH > ULN: WITH ALL OTHER T3/T4 TEST ≥ LLN
|
7 Participants
|
9 Participants
|
7 Participants
|
2 Participants
|
25 Participants
|
4 Participants
|
3 Participants
|
7 Participants
|
8 Participants
|
33 Participants
|
40 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH > ULN: WITH AT LEAST ONE T3/T4 TEST < LLN
|
5 Participants
|
6 Participants
|
5 Participants
|
2 Participants
|
18 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
5 Participants
|
23 Participants
|
26 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH > ULN: WITH FT3/FT4 TEST MISSING
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH < LLN
|
3 Participants
|
7 Participants
|
7 Participants
|
3 Participants
|
20 Participants
|
4 Participants
|
1 Participants
|
5 Participants
|
14 Participants
|
34 Participants
|
39 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH < LLN: WITH TSH >= LLN AT BASELINE
|
3 Participants
|
7 Participants
|
7 Participants
|
3 Participants
|
20 Participants
|
3 Participants
|
0 Participants
|
3 Participants
|
14 Participants
|
34 Participants
|
37 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH < LLN: WITH ALL OTHER FT3/FT4 TEST ≤ ULN
|
2 Participants
|
6 Participants
|
6 Participants
|
3 Participants
|
17 Participants
|
4 Participants
|
1 Participants
|
5 Participants
|
11 Participants
|
28 Participants
|
33 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH < LLN: WITH AT LEAST ONE T3/T4 TEST > ULN
|
3 Participants
|
3 Participants
|
3 Participants
|
2 Participants
|
11 Participants
|
2 Participants
|
0 Participants
|
2 Participants
|
8 Participants
|
19 Participants
|
21 Participants
|
|
Laboratory Abnormalities: Specific Thyroid Tests
TSH < LLN: WITH FT3/FT4 TEST MISSING
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants
the total number of participants whose best overall response (BOR) is either irCR or irPR divided by the total number of response-evaluable participants.
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Objective Response Rate
|
21 Percentage of Participants
Interval 4.7 to 50.8
|
47 Percentage of Participants
Interval 23.0 to 72.2
|
50 Percentage of Participants
Interval 24.7 to 75.3
|
50 Percentage of Participants
Interval 11.8 to 88.2
|
42 Percentage of Participants
Interval 28.1 to 55.9
|
53 Percentage of Participants
Interval 27.8 to 77.0
|
19 Percentage of Participants
Interval 4.0 to 45.6
|
36 Percentage of Participants
Interval 20.4 to 54.9
|
44 Percentage of Participants
Interval 28.5 to 60.3
|
43 Percentage of Participants
Interval 32.4 to 53.2
|
41 Percentage of Participants
Interval 32.3 to 50.0
|
SECONDARY outcome
Timeframe: Up to 3 YearsPopulation: All Treated Participants
the time from the first dose of study drug until the first documentation of irCR or irPR, as related to current database lock date or most current tumor measurement
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Time to Response
|
11.9 Weeks
Interval 11.9 to 12.9
|
11.9 Weeks
Interval 7.7 to 14.7
|
11.9 Weeks
Interval 7.0 to 18.7
|
12.3 Weeks
Interval 10.4 to 18.0
|
11.9 Weeks
Interval 7.0 to 18.7
|
8 Weeks
Interval 7.4 to 34.1
|
15.7 Weeks
Interval 7.7 to 16.0
|
9.6 Weeks
Interval 7.4 to 34.1
|
12.1 Weeks
Interval 11.0 to 24.1
|
12 Weeks
Interval 7.0 to 24.1
|
12 Weeks
Interval 7.0 to 34.1
|
SECONDARY outcome
Timeframe: from the first documented response (irCR or irPR) until progression or deathPopulation: All Treated Participants with a response
the time from the first documented response (irCR or irPR) until progression or death, whichever occurs first. For participants who did not progress or die, duration of response will be censored on the date of the last tumor assessment.
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=53 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=3 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=33 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=94 Participants
All participants who received both BMS and Ipi
|
Total
n=127 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Duration of Response
|
NA Weeks
Interval 78.4 to
Not a sufficient amount of responders to calculate median duration of response.
|
105 Weeks
Interval 105.0 to 141.0
|
66.3 Weeks
Interval 66.3 to
insufficient number of responders in order to derive 95%CI
|
59.1 Weeks
Interval 31.3 to 86.9
|
105 Weeks
Interval 86.9 to 141.0
|
73.1 Weeks
Interval 73.1 to
upper limit number not reached
|
64.3 Weeks
upper limit number not reached
lower limit number: insufficient number of responders in order to derive 95%CI
|
73.1 Weeks
Interval 64.3 to
insufficient number of responders in order to derive 95%CI
|
NA Weeks
Not a sufficient amount of responders to calculate median duration of response.
lower limit number: insufficient number of responders in order to derive 95%CI
|
105 Weeks
Interval 78.4 to 141.0
|
105 Weeks
Interval 78.4 to 141.0
|
SECONDARY outcome
Timeframe: 156 weeksPopulation: All Treated Participants
the time from the first dose to the first observation of disease progression or death due to any cause. If a participant has not progressed or died at the time of analysis, PFS will be censored on the date of the last disease assessment. Participants who did not have any on-study tumor assessments and did not die will be censored on the date of the first dose of study medication.
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=17 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
combined total of participants who receive BMS only
|
Cohort 8
n=41 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
All participants who received both BMS and Ipi
|
Total
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Progression Free Survival
|
12.50 Weeks
Interval 11.6 to 47.9
|
64.40 Weeks
Interval 12.0 to 149.0
|
58.40 Weeks
Interval 12.0 to
Upper limit number not reached
|
33.55 Weeks
Interval 11.6 to 97.1
|
—
|
24.60 Weeks
Interval 8.1 to
Upper limit number not reached
|
12.15 Weeks
Interval 7.7 to 23.9
|
—
|
37.10 Weeks
Interval 12.9 to
Upper limit number not reached
|
—
|
—
|
SECONDARY outcome
Timeframe: Up to 3 yearsPopulation: All Treated Participants with baseline and at least one post baseline assessment
Serum samples will be collected to evaluate the development of antibodies to BMS-936558 and to ipilimumab.
Outcome measures
| Measure |
Cohort 1
n=13 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=5 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
n=51 Participants
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=15 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=12 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
n=27 Participants
combined total of participants who receive BMS only
|
Cohort 8
n=35 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
n=86 Participants
All participants who received both BMS and Ipi
|
Total
n=113 Participants
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With an Anti-Drug Antibody (ADA) Response for Nivolumab (Nivo) and Ipilimumab (Ipi)
Baseline ADA Positive (nivo)
|
1 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
4 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
5 Participants
|
6 Participants
|
|
Number of Participants With an Anti-Drug Antibody (ADA) Response for Nivolumab (Nivo) and Ipilimumab (Ipi)
Baseline ADA Positive (ipi)
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
|
Number of Participants With an Anti-Drug Antibody (ADA) Response for Nivolumab (Nivo) and Ipilimumab (Ipi)
ADA Positive (nivo)
|
6 Participants
|
10 Participants
|
4 Participants
|
0 Participants
|
20 Participants
|
4 Participants
|
1 Participants
|
5 Participants
|
10 Participants
|
30 Participants
|
35 Participants
|
|
Number of Participants With an Anti-Drug Antibody (ADA) Response for Nivolumab (Nivo) and Ipilimumab (Ipi)
ADA Positive (ipi)
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
2 Participants
|
4 Participants
|
|
Number of Participants With an Anti-Drug Antibody (ADA) Response for Nivolumab (Nivo) and Ipilimumab (Ipi)
ADA Negative (nivo)
|
7 Participants
|
7 Participants
|
12 Participants
|
5 Participants
|
31 Participants
|
11 Participants
|
11 Participants
|
22 Participants
|
25 Participants
|
56 Participants
|
78 Participants
|
|
Number of Participants With an Anti-Drug Antibody (ADA) Response for Nivolumab (Nivo) and Ipilimumab (Ipi)
ADA Negative (ipi)
|
12 Participants
|
17 Participants
|
16 Participants
|
5 Participants
|
50 Participants
|
13 Participants
|
10 Participants
|
23 Participants
|
31 Participants
|
81 Participants
|
104 Participants
|
SECONDARY outcome
Timeframe: Up to 64 WeeksPopulation: All Treated Participants with quantifiable data
The peak and trough concentrations of BMS-936558 (MDX-1106) and ipilimumab in participants with quantifiable data
Outcome measures
| Measure |
Cohort 1
n=14 Participants
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 Participants
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 Participants
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Any BMS and Ipi Combo
All participants who received treatment in Cohorts 1 through 3
|
Cohort 6
n=7 Participants
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=10 Participants
3 mg/kg of BMS-936558 (MDX-1106)
|
Only BMS
combined total of participants who receive BMS only
|
Cohort 8
n=40 Participants
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
Any BMS/Ipi
All participants who received both BMS and Ipi
|
Total
All Participants who received treatment in any cohort combined
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Peak and Trough Concentrations
Ipi Peak (Cmax)
|
63.9 ug/mL
Geometric Coefficient of Variation 17.7
|
68.5 ug/mL
Geometric Coefficient of Variation 20.4
|
19.8 ug/mL
Geometric Coefficient of Variation 40.6
|
63.2 ug/mL
Geometric Coefficient of Variation 24.2
|
—
|
—
|
—
|
—
|
63.5 ug/mL
Geometric Coefficient of Variation 31.5
|
—
|
—
|
|
Peak and Trough Concentrations
Ipi Trough (Cmin)
|
9.7 ug/mL
Geometric Coefficient of Variation 33.7
|
11.9 ug/mL
Geometric Coefficient of Variation 29.5
|
3.6 ug/mL
Geometric Coefficient of Variation 30.4
|
9.2 ug/mL
Geometric Coefficient of Variation 34.4
|
—
|
—
|
—
|
—
|
9.8 ug/mL
Geometric Coefficient of Variation 43.7
|
—
|
—
|
|
Peak and Trough Concentrations
Nivo Peak (Cmax)
|
6.5 ug/mL
Geometric Coefficient of Variation 17.2
|
21.5 ug/mL
Geometric Coefficient of Variation 17.9
|
49.8 ug/mL
Geometric Coefficient of Variation 24.7
|
63.4 ug/mL
Geometric Coefficient of Variation 18.0
|
—
|
20.5 ug/mL
Geometric Coefficient of Variation 64.5
|
97.7 ug/mL
Geometric Coefficient of Variation 52.5
|
—
|
18.1 ug/mL
Geometric Coefficient of Variation 38.1
|
—
|
—
|
|
Peak and Trough Concentrations
Nivo Trough (Cmin)
|
1.5 ug/mL
Geometric Coefficient of Variation 44.9
|
2.6 ug/mL
Geometric Coefficient of Variation 94.4
|
27.7 ug/mL
Geometric Coefficient of Variation 23.9
|
23.9 ug/mL
Geometric Coefficient of Variation 37.5
|
—
|
13.2 ug/mL
Geometric Coefficient of Variation 40.9
|
53.1 ug/mL
Geometric Coefficient of Variation 49.8
|
—
|
5.9 ug/mL
Geometric Coefficient of Variation 49.3
|
—
|
—
|
Adverse Events
Cohort 1
Serious events: 10 serious events
Other events: 14 other events
Deaths: 8 deaths
Cohort 2
Serious events: 15 serious events
Other events: 17 other events
Deaths: 4 deaths
Cohort 2a
Serious events: 10 serious events
Other events: 16 other events
Deaths: 2 deaths
Cohort 3
Serious events: 5 serious events
Other events: 6 other events
Deaths: 0 deaths
Cohort 6
Serious events: 9 serious events
Other events: 17 other events
Deaths: 7 deaths
Cohorot 7
Serious events: 10 serious events
Other events: 15 other events
Deaths: 8 deaths
Cohort 8
Serious events: 26 serious events
Other events: 41 other events
Deaths: 8 deaths
Serious adverse events
| Measure |
Cohort 1
n=14 participants at risk
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 participants at risk
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 participants at risk
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 participants at risk
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 6
n=17 participants at risk
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 participants at risk
3 mg/kg of BMS-936558 (MDX-1106)
|
Cohort 8
n=41 participants at risk
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
|---|---|---|---|---|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
Pleural Effusion
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary Edema
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Vomiting
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Colitis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Nausea
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Pancreatitis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Pain
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Asthenia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Disease Progression
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Pyrexia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Alanine Aminotransferase Increased
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Aspartate Aminotransferase Increased
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Creatinine Increased
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Superinfection
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Urinary Tract Infections
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Hepatobiliary disorders
Cholecystitis Acute
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Immune system disorders
Autoimmune Disorder
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Dehydration
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Pain in Extremity
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Convulsions
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Tubulointerstitial Nephritis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Abdominal Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Appendix Disorders
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Small Intestinal Obstruction
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Amylase Increased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Lipase Increased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Decreased Appetite
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Deep Vein Thrombosis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Hypertension
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Hypotension
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Uveitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Vision Blurred
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Headache
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Central Nervous System Necrosis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary Embolism
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Adrenal Insufficiency
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Thyroiditis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Chorioretinitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Muscular Weakness
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Psychiatric disorders
Confusional State
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Renal Failure Acute
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Diverticular Perforation
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Urea Increased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Troponin 1 Increased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Supraventricular Tachycardia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Hepatobiliary disorders
Hyperbilirubinemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Neck Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Cerebral Ischemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Viral Infection
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Diarrhea
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.1%
7/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Death
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Sudden Death
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Hypophysitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Back Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain Neoplasm
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastasis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Blood and lymphatic system disorders
Anemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Atrial Fibrillation
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Device Related Infection
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Sepsis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Psychiatric disorders
Mental Status Changes
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Chest Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Failure to Thrive
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hyperuricemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Bone Lesion
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Cognitive Disorders
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Syncope
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Surgical and medical procedures
Hospitalizations
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Gastrointestinal Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Aphasia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Dysarthria
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Urinary Tract Infection
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Multiorgan Failure
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Edema Peripheral
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Enterococcal Sepsis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Infection
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Dry Eye
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Embolism
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Alkaline Phosphatase Increased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Hemorrhage
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Blood and lymphatic system disorders
Hemolysis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastasis to Central Nervous System
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Central Nervous System Hemorrhage
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Hepatobiliary disorders
Acute Cholecystitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Troponin T Increased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Fatigue
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Urinary Tract Obstruction
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Pneumonitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
Other adverse events
| Measure |
Cohort 1
n=14 participants at risk
0.3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2
n=17 participants at risk
1 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 2a
n=16 participants at risk
3 mg/kg of BMS-936558 (MDX-1106) + 1 mg/kg of ipilimumab
|
Cohort 3
n=6 participants at risk
3 mg/kg of BMS-936558 (MDX-1106) + 3 mg/kg of ipilimumab
|
Cohort 6
n=17 participants at risk
1mg/kg of BMS-936558 (MDX-1106)
|
Cohorot 7
n=16 participants at risk
3 mg/kg of BMS-936558 (MDX-1106)
|
Cohort 8
n=41 participants at risk
1 mg/kg of BMS-936558 (MDX-1106) in combination with 3 mg/kg of ipilimumab every 3 weeks for 4 doses
|
|---|---|---|---|---|---|---|---|
|
Skin and subcutaneous tissue disorders
Skin Fissures
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Acute Febrile Neutrophilic Dermatosis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Tonsillitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Blister
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Butterfly Rash
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Dermatitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Hair Color Changes
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Nausea
|
50.0%
7/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
29.4%
5/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
25.0%
4/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
50.0%
3/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
37.5%
6/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
48.8%
20/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Diarrhea
|
35.7%
5/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
35.3%
6/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
50.0%
8/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
66.7%
4/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
25.0%
4/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
41.5%
17/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Constipation
|
28.6%
4/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
25.0%
4/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
33.3%
2/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
25.0%
4/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
24.4%
10/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Abdominal Pain
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
26.8%
11/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Vomiting
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
24.4%
10/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Dry Mouth
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
14.6%
6/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Flatulence
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
14.6%
6/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Abdominal Distension
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Abdominal Pain Upper
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Gastroesophageal Reflux Disease
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Hemorrhoids
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Gingival Pain
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Glossodynia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Tongue Ulceration
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Anal Pruritis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Anorectal Discomfort
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Aphthous Stomatitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Cheilitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Gingival Bleeding
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Lip Dry
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Regurgitation
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Tongue Discoloration
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Gastrointestinal disorders
Tongue Edema
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Rash
|
64.3%
9/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
64.7%
11/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
68.8%
11/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
66.7%
4/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
41.2%
7/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
31.2%
5/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
65.9%
27/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
57.1%
8/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
64.7%
11/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
75.0%
12/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
50.0%
3/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
25.0%
4/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
53.7%
22/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Vitiligo
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.2%
5/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Dry Skin
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.2%
5/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Night Sweats
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Erythema
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Rash Papular
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.2%
5/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Rash Pruritic
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Rash Macular
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Palmar-Plantar Erythrodysaesthesia Syndrome
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Rash Maculo-Papular
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Lichenoid Keratosis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Photodermatosis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Photosensitivity Reaction
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Skin and subcutaneous tissue disorders
Skin Irritation
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Fatigue
|
64.3%
9/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
64.7%
11/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
43.8%
7/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
66.7%
4/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
52.9%
9/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
43.8%
7/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
63.4%
26/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Pyrexia
|
35.7%
5/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
41.2%
7/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
66.7%
4/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
25.0%
4/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
34.1%
14/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Chills
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
29.4%
5/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.1%
7/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Edema Peripheral
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
33.3%
2/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Asthenia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Edema
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Chest Pain
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Chest Discomfort
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Influenza Like Illness
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Mucosal Inflammation
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Xerosis
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Axillary Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Local Swelling
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Thirst
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Catheter Site Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Early Satiety
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Facial Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Feeling Jittery
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Hernia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Injection Site Reaction
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
General disorders
Sensation of Foreign Body
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
35.7%
5/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
35.3%
6/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
43.8%
7/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
33.3%
2/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
29.4%
5/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
37.5%
6/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
41.5%
17/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.1%
7/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal Congestion
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
14.6%
6/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea Exertional
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus Congestion
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Upper-Airway Cough Syndrome
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Productive Cough
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory Tract Inflammation
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Throat Tightness
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary Mass
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep Apnea Syndrome
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Arthalgia
|
35.7%
5/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
33.3%
2/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
43.8%
7/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
29.3%
12/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Back Pain
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
25.0%
4/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
33.3%
2/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Pain in Extremity
|
28.6%
4/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Muscle Spasms
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal Chest Pain
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Neck Pain
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Joint Swelling
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Flank Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Pain in Jaw
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Groin Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Joint Stiffness
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Muscle Tightness
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal Stiffness
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Lipase Increased
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
66.7%
4/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
19.5%
8/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Amylase Increased
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
50.0%
3/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
14.6%
6/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Aspartate Aminotransferase Increased
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
66.7%
4/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.1%
7/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Weight Decreased
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
33.3%
2/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.2%
5/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Alanine Aminotransferase Increased
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
33.3%
2/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.1%
7/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Hemoglobin Decreased
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Weight Increased
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Lactate Dehydrogenase Increased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
14.6%
6/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Alkaline Phosphatase Increased
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Creatinine Increased
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Gamma-Glutamyltransferase Increased
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Thyroid Stimulating Hormone Decreased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Electrocardiogram QT Prolonged
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
International Normalized Ratio Increased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Albumin Decreased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Phosphorus Increased
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Potassium Increased
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Testosterone Decreased
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Blood Uric Acid Increased
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Breath Sounds Abnormal
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Chest X-Ray Abnormal
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Fungal Test Positive
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Thyroid Function Test Abnormal
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Investigations
Transaminases Increased
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Headache
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
47.1%
8/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
25.0%
4/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
66.7%
4/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
31.7%
13/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Dizziness
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Neuropathy Peripheral
|
28.6%
4/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Dysgeusia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Ataxia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Hypoaesthesia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Tremor
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Ageusia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Amnesia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Lethargy
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Carpal Tunnel Syndrome
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Cognitive Disorder
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Dizziness Postural
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Dysarthria
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Memory Impairment
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Migraine with Aura
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Mononeuropathy
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Narcolepsy
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Sciatica
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Sinus Headache
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Decreased Appetite
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
23.5%
4/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.2%
5/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
19.5%
8/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Dehydration
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hyperuricemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hyperphosphatemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Increased Appetite
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Metabolism and nutrition disorders
Polydipsia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Upper Respiratory Tract Infections
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Urinary Tract Infections
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
17.6%
3/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Candida Infection
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Conjunctivitis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Oral Herpes
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Herpes Zoster
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Influenza
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Appendicitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Cellulitis Orbital
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Clostridium Difficile Colitis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Escherichia Bacteremia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Respiratory Syncytial Virus Infection
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Tooth Abscess
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Viral Infection
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Infections and infestations
Wound Infection
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Vision Blurred
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
33.3%
2/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Dry Eye
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Uveitis
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Ocular Hyperemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Eye Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Eye Pruritus
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Eye Swelling
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Eyelid Margin Crusting
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Hypermetropia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Ophthalmoplegia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Photophobia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Eye disorders
Vitreous Floaters
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Hypothyroidism
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
14.6%
6/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Hypophysitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Thyroiditis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Endocrine disorders
Adrenal Insufficiency
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Hypertension
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
18.8%
3/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Hypotension
|
21.4%
3/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Flushing
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Hemorrhage
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Deep Vein Thrombosis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Hot Flush
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Vascular disorders
Thrombophlebitis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Psychiatric disorders
Insomnia
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
9.8%
4/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Psychiatric disorders
Anxiety
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Psychiatric disorders
Depression
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
4.9%
2/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Psychiatric disorders
Confusional State
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Psychiatric disorders
Mood Altered
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Psychiatric disorders
Mental Status Changes
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Blood and lymphatic system disorders
Lymphopenia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Blood and lymphatic system disorders
Anemia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Blood and lymphatic system disorders
Iron Deficiency Anemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Blood and lymphatic system disorders
Lymph Node Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Blood and lymphatic system disorders
Neutropenia
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Sunburn
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Fall
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Infusion Related Reaction
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Alcohol Poisoning
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Laceration
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Procedural Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Radiation Necrosis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Radiation Skin Injury
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Injury, poisoning and procedural complications
Wound
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Pollakiuria
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Dysuria
|
14.3%
2/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Hematuria
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
12.5%
2/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Micturition Urgency
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Chromaturia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Polyuria
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Urethral Discharge
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Renal and urinary disorders
Urinary Tract Disorder
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
7.3%
3/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
11.8%
2/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Atrial Fibrillation
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Angina Pectoris
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Atrioventricular Block First Degree
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Cardiac disorders
Pericardial Effusion
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Ear and labyrinth disorders
Ear Pain
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Ear and labyrinth disorders
Hearing Impaired
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Ear and labyrinth disorders
Ear Pruritus
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Ear and labyrinth disorders
Hypoacusis
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor Pain
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acrochordon
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal Cell Carcinoma
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous Cell Carcinoma
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumor Hemorrhage
|
7.1%
1/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Reproductive system and breast disorders
Breast Cyst
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Reproductive system and breast disorders
Gynecomastia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Reproductive system and breast disorders
Polymenorrhea
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Reproductive system and breast disorders
Vaginal Hemorrhage
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
5.9%
1/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Reproductive system and breast disorders
Vulvovaginal Dryness
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
6.2%
1/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
2.4%
1/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
|
Hepatobiliary disorders
Hyperbilirubinemia
|
0.00%
0/14 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
16.7%
1/6 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/17 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/16 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
0.00%
0/41 • Within 100 days of discontinuation of dosing or within 30 days of the last visit for screen failures (Approximately 3 years)
The Following arms: Any BMS and Ipi Combo, Only BMS and Total, were left out of the AE section because the participants in those arms are reflected in the other arms.
|
Additional Information
Bristol-Myers Squibb Study Director
Bristol-Myers Squibb
Phone: Please Email
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60